Skip to main content

Table 1 ᅟ

From: Correction to: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

  Baseline Plausible range for sensitivity analysis Sources
Parameters
 Discount rate 0.03 0 0.03 [31]
 Vaccine coverage 25.3% 10% 28.6% [36, 37]
 Mortality rate 0.0058% 0.000029 0.000039 [41]
 Rotateq efficacy 98% 0.883 1 [38, 42]
 Rotateq infected 0.018% 0 0.00018 [42]
 hospitalization1a 44% 0 0.44 [22]
 Outpatient1 a 28% 0 0.28 [22]
 Home-care1 a 28% 0 0.28 [22]
 Rotarix infected 0.1% 0 0.001 [26]
 LLR infected 0.9% 0 0.009 [41]
 hospitalization3c 0.2% 0 0.002 [2]
 Outpatient3 c 7.9% 0 0.079 [2]
 home-care3 c 91.9% 0 0.919 [2]
 Rotarix efficacy 96.1% 0.871 1 [25, 26]
 LLR efficacy 72% 0.63 0.79 [27]
 Infection rate 78.85% 0 0.7885 [21, 45]
 home-care2b 32% 0 0.32 [22]
 hospitalization2 b 33% 0 0.33 [22]
 Outpatient2 b 35% 0 0.35 [22]
 natural protact1d 77% 0 0.77 [23]
 natural protact2 d 83% 0 0.83 [23]
Costs
 International vaccinations 200.00 50 250 [16, 17]
 LLR vaccination 24    The national tariff
 Hospitalizations 570.04 0 570.04 [43]
 Outpatient 104.19 0 104.19 [43]
 Home-care 11.52 0 11.52 [44]
Health Effects
 QALY(Hospitalization) 0.077 0.075 0.078 [30]
 QALY(Outpatient) 0.081 0 0.081 [30]
 QALY(Home-care) 0.082 0 0.082 [30]
\